Newswise — BUFFALO, N.Y. — A new study from Roswell Park Cancer Institute reporting the findings of the first clinical trial to evaluate the immune effects of high-dose radiation therapy followed by surgery in patients with advanced kidney cancer may also set the stage for combination treatments with immunotherapy. The research, published in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR), shows that nephrectomy can be effectively paired with stereotactic body radiation therapy (SBRT), and also provides strong evidence that immunotherapy may be an effective third element to incorporate into this combination therapy strategy.
In a pilot clinical study, 14 patients with metastatic renal cell carcinoma (mRCC) were treated with SBRT in a single administration, or fraction, followed four weeks later by cytoreductive nephrectomy, or surgery to remove or reduce the size of their tumors. The team set out to assess the safety and feasibility of this approach and analyze the immunological impact of high-dose radiation. Based on their preliminary studies in the lab, the team monitored patients’ tumors for expression of immunomodulatory molecules and tumor-associated antigens.
“We saw a significant increase in calreticulin and other molecules that stimulate T cells,” says the paper’s first author, Anurag Singh, MD, Professor of Oncology and Director of Radiation Research with the Department of Radiation Medicine at Roswell Park. “This suggests that it may be possible to improve the effectiveness of immunotherapies by first priming the pump with high-dose radiation.”
The authors include a contributor from the Department of Radiation Oncology at the Medical University of South Carolina. The study, “A Pilot Study of Stereotactic Body Radiation Therapy Combined with Cytoreductive
Nephrectomy for Metastatic Renal Cell Carcinoma,” is available at clincancerres.aacrjournals.org.
Findings from this research will also be presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting in San Diego Sept. 24-27, where Dr. Singh will receive a Basic/Translational Science Abstract Award for his role in this work. The research was supported by grants from the National Center for Advancing Translational Sciences (project no. UL1TR001412), National Cancer Institute (project nos. P30CA016056 and R01CA140622), the Sklarow Foundation, Elsa Kreiner Memorial Fund, Fraternal Order of Eagles and RPCI Friends of Urology.
This release is also available on the Roswell Park website: https://www.roswellpark.org/media/news/surgery-and-high-dose-sbrt-radiation-can-be-combined-treat-kidney-cancer-roswell-park
Editor’s note: See a video interview with Dr. Thomas Schwaab, co-last author on this research, at https://youtu.be/V1jjfu4MFMA.
The mission of Roswell Park Cancer Institute (RPCI) is to understand, prevent and cure cancer. Founded in 1898, RPCI is one of the first cancer centers in the country to be named a National Cancer Institute-designated comprehensive cancer center and remains the only facility with this designation in Upstate New York. The Institute is a member of the prestigious National Comprehensive Cancer Network, an alliance of the nation’s leading cancer centers; maintains affiliate sites; and is a partner in national and international collaborative programs. For more information, visit www.roswellpark.org, call 1-877-ASK-RPCI (1-877-275-7724) or email email@example.com. Follow Roswell Park on Facebook and Twitter.